Determined by a cell proliferation assay using serum free human MCF-7 cells. The EC50 is 0.71-1.8 ng/ml.
Product Details
Product Details
Product Specification
| Species | Salmon |
| Synonyms | LR3 Insulin-like Growth Factor-I, MGF, IGFI, IGF1A, IGF, IBP1 |
| Accession | Q91476 |
| Amino Acid Sequence | Gly19-Ala88 (Glu21Arg) |
| Expression System | E.coli |
| Molecular Weight | 10-12 kDa (Reducing) |
| Purity | >95% by SDS-PAGE & HPLC. |
| Endotoxin | <0.1EU/μg |
| Conjugation | Unconjugated |
| Tag | No Tag |
| Physical Appearance | Lyophilized powder |
| Storage Buffer | PBS, pH7.4 |
| Reconstitution | Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation. |
| Stability & Storage | ·12 months from date of receipt, lyophilized powder stored at -20 to -80℃. |
| Reference | Endocrinology. 1999 Oct;140(10):4699-705. |
Background
IGF-I is a well-characterized basic peptide secreted by the liver that circulates in the blood. It has growth-regulating, insulin-like, mitogenic activities. IGF-I is a growth factor that has a major, but not absolute, dependence on somatotropin. It is believed to be mainly active in adults in contrast to IGF-II, which is also a major fetal growth factor. Salmon Long R3 Insulin-like Growth Factor-I contains a 70 amino acid analog of Salmon IGF-I. Compared to the complete IGF-I sequence, an addition of the LR3-IGF-1 includes the substitution of an Arg for the Glu at position 3 (hence R3) and a 13 amino acid extension peptide at the N-terminus. An enhanced potency is due to the markedly decreased binding of Long R3-IGF-I to IGF binding proteins which normally inhibit the biological actions of IGFs.
Picture
Picture
Bioactivity
SDS-PAGE
2μg (R: reducing condition, N: non-reducing condition).
SEC-HPLC
>95% as determined by SEC-HPLC.
